Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gerald Batist

Showing results (51-60 of 165) with videos related to

Pageof 17
Sort By:
Bioorganic & Medicinal Chemistry|May 2, 2002
Design and syntheses of putative bioactive taxanesAnastasia Nikolakakis, Jian Hui Wu, Gerald Batist, et al.
Human Vaccines & Immunotherapeutics|April 16, 2016
Co-prevalence of Epstein-Barr virus and high-risk human papillomaviruses in Syrian women with breast cancerAla-Eddin Al Moustafa, Noor Al-Antary, Tahar Aboulkassim, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|June 20, 2020
A Phase I, Dose Escalation, Single Dose Trial of Oral Attenuated Salmonella typhimurium Containing Human IL-2 in Patients With Metastatic Gastrointestinal CancersThomas J Gniadek, Lance Augustin, Janet Schottel, et al.
Cancer Immunology, Immunotherapy : CII|January 27, 2026
A phase 2 study of orally administered live biotherapeutic salmonella-IL2 with FOLFIRINOX for stage IV pancreatic cancerGerald Batist, Petr Kavan, Lance Augustin, et al.
Frontiers in Oncology|August 27, 2019
Precision Medicine Tools to Guide Therapy and Monitor Response to Treatment in a HER-2+ Gastric Cancer Patient: Case ReportAdriana Aguilar-Mahecha, Sarah Joseph, Luca Cavallone, et al.
Cell Reports|September 13, 2023
A NRF2 inhibitor selectively sensitizes KEAP1 mutant tumor cells to cisplatin and gefitinib by restoring NRF2-inhibitory function of KEAP1 mutantsTahar Aboulkassim, Xiaohong Tian, Qiang Liu, et al.
Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual International Conference|November 25, 2010
Magnetotactic bacteria penetration into multicellular tumor spheroids for targeted therapyNisryn Mokrani, Ouajdi Felfoul, Fatemeh Afkhami Zarreh, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 15, 2014
Imiquimod in the treatment of breast cancer skin metastasisLisa Henriques, Michael Palumbo, Marie-Pascale Guay, et al.
Current Oncology (Toronto, Ont.)|January 14, 2021
Lung Cancer Pre-Diagnostic Pathways from First Presentation to Specialist ReferralSatya Rashi Khare, Sreenath Arekunnath Madathil, Gerald Batist, et al.
The Oncologist|January 8, 2011
In the end what matters most? A review of clinical endpoints in advanced breast cancerSunil Verma, Deanna McLeod, Gerald Batist, et al.
Pageof 17

Showing results (51-60 of 165) with videos related to

Sort By:
Pageof 17
Bioorganic & Medicinal Chemistry|May 2, 2002
Design and syntheses of putative bioactive taxanesAnastasia Nikolakakis, Jian Hui Wu, Gerald Batist, et al.
Human Vaccines & Immunotherapeutics|April 16, 2016
Co-prevalence of Epstein-Barr virus and high-risk human papillomaviruses in Syrian women with breast cancerAla-Eddin Al Moustafa, Noor Al-Antary, Tahar Aboulkassim, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|June 20, 2020
A Phase I, Dose Escalation, Single Dose Trial of Oral Attenuated Salmonella typhimurium Containing Human IL-2 in Patients With Metastatic Gastrointestinal CancersThomas J Gniadek, Lance Augustin, Janet Schottel, et al.
Cancer Immunology, Immunotherapy : CII|January 27, 2026
A phase 2 study of orally administered live biotherapeutic salmonella-IL2 with FOLFIRINOX for stage IV pancreatic cancerGerald Batist, Petr Kavan, Lance Augustin, et al.
Frontiers in Oncology|August 27, 2019
Precision Medicine Tools to Guide Therapy and Monitor Response to Treatment in a HER-2+ Gastric Cancer Patient: Case ReportAdriana Aguilar-Mahecha, Sarah Joseph, Luca Cavallone, et al.
Cell Reports|September 13, 2023
A NRF2 inhibitor selectively sensitizes KEAP1 mutant tumor cells to cisplatin and gefitinib by restoring NRF2-inhibitory function of KEAP1 mutantsTahar Aboulkassim, Xiaohong Tian, Qiang Liu, et al.
Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual International Conference|November 25, 2010
Magnetotactic bacteria penetration into multicellular tumor spheroids for targeted therapyNisryn Mokrani, Ouajdi Felfoul, Fatemeh Afkhami Zarreh, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 15, 2014
Imiquimod in the treatment of breast cancer skin metastasisLisa Henriques, Michael Palumbo, Marie-Pascale Guay, et al.
Current Oncology (Toronto, Ont.)|January 14, 2021
Lung Cancer Pre-Diagnostic Pathways from First Presentation to Specialist ReferralSatya Rashi Khare, Sreenath Arekunnath Madathil, Gerald Batist, et al.
The Oncologist|January 8, 2011
In the end what matters most? A review of clinical endpoints in advanced breast cancerSunil Verma, Deanna McLeod, Gerald Batist, et al.
Pageof 17